《大行報告》麥格理:中國平安(02318.HK)首季業績或再令人失望 重申「跑輸大市」評級
麥格理髮表研究報告指出,中國平安(02318.HK)將於下週五(29日)披露今年首季業績,該行預期首季表現或再次令人失望,料公司對次季的指引將轉向更爲負面,因最近的疫情封鎖將影響壽險業務銷售及向中小企業貸款資產質量。
該行指出,由於中國平安去年剩餘邊際按年跌5%,因此預期集團及其壽險子公司今年首季稅後營運溢利按年跌5%至10%;另估計公司代理人數首季按年跌40%至45%,拖累新業務價值的增長;大市疲弱導致短期投資變動虧損擴大,相信難以實現5%的投資回報,預期稅後淨利潤或令人失望。該行維持對中國平安的目標價爲42元,重申「跑輸大市」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.